Insulin glargine with the trade name Lantus is a long-acting basal insulin analog, given once daily to help control the blood sugar level of those with diabetes.
The medical name for Lantus is insulin glargine; it refers to the ways of modifying the DNA of human insulin to form the analog.
It has been specifically designed to overcome the deficiencies of traditionally available “intermediate-acting” insulins that are currently used for basal insulin supplementation.
According to the insulin glargine package insert, this medication consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a “peakless” profile.
This drug is used to improve blood sugar control in adults and children with diabetes mellitus.
The Lantus price for subcutaneous solution (100 units/mL) is around $306 for a supply of 10 milliliters, depending on the pharmacy you visit.
In 2000: the launching of Lantus by Sanofi-Aventis Germany Ltd in the entire European Union was approved formally by the European Commission. This admission was prolonged in 2005.
In 2009: it hit the news over concerns that it may lead to the formation of cancer. But, the European Medicines Agency (EMEA) found the evidence suggesting the link to be inconclusive and cleared the drug for further use.
In 2017: 2.3 million people have been prescribed Lantus. It is one of the most tested long-acting insulins in the world, with 500 clinical trials and 2counting.
If you are looking for a Turkish pharmaceutical exporter for inquiries Lantus please contact Dano Health Group.
Lantus is used to treat
- Type 1 Diabetes Mellitus in adult patients; it helps to improve glycemic control.
- Type 2 Diabetes Mellitus in adult patients for whom oral hypoglycemic agents have not shown to be sufficiently effective; it helps to improve glycemic control.
- Type 1 diabetes in children who are at least 6 years old.
It may be used with a shorter-acting insulin product; it can be used alone or with other diabetes drugs.
Lantus in the long-acting class is considered basal insulin that is administered once a day. Its duration of action is prolonged; there is no distinct insulin peak so that it is suitable for once-daily administration and reduces the risk of nocturnal hypoglycemia seen with intermediate-acting insulins.
Generally, Lantus function begins about one to two hours after injection, peaks in six hours, and continues working for 18 to 26 hours. But, everyone is different. Sometimes, Lantus does not last a full 24 hours, so they see higher glucose numbers for the couple hours before injection time; for some others, it may last longer, so the previous day’s dose may still be working for a couple of hours past injection time.
Insulin glargine and natural human insulin work the same way, but Insulin glargine’s action lasts longer and helps diabetic patients regulate glucose or sugar in the body. It helps to promote the movement of sugar from the blood into body tissues and also stops sugar production in the liver.
This medication was manufactured by Sanofi-Aventis and has been available for pharmaceutical use since 2000. The development of it was conducted at Sanofi-Aventis’s biotechnology competence center in Frankfurt-Höchst.
This company supplies the product to over 100 countries and more than 3,5 million patients worldwide; So this makes Lantus Germany’s largest and most important export pharmaceutical product. Dano Health as a Turkish pharmaceutical exporter also witnesses such growth.
Sanofi-Aventis increased its turnover with this drug around 28% to 2,45 Billion €, therefrom 130 Million € in Germany with approx. 1.8 million people with diabetes use the product.
It was the 15th highest selling pharmaceutical product in Germany in 2007 and has led the way for years now, both in diabetes sales and in Sanofi sales and pumping out more than $7 billion worldwide for the company at its peak.
Insulin Glargine Market Size
With the slow down in world economic growth, the industry of this medication has also suffered a certain impact especially clinical trial product distributors, but still maintained a relatively optimistic growth during the past four years; the average annual growth rate of the Insulin Glargine market was 7600 million $ in 2013 that increases to 8590 million $ in 2016.
According to the BisReport analysts, the Insulin Glargine market size will be further expanded slowdown during the next few years; they expect that by 2021, the named-patient drug distributor market size of the Insulin Glargine will reach 9700 million $.